BioArctic AB (publ) (ST:BIOA-B) — Market Cap & Net Worth
Market Cap & Net Worth: BioArctic AB (publ) (BIOA-B)
BioArctic AB (publ) (ST:BIOA-B) has a market capitalization of $2.54 Billion (Skr23.59 Billion) as of September 16, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #5406 globally and #73 in its home market, demonstrating a -3.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioArctic AB (publ)'s stock price Skr317.40 by its total outstanding shares 74324489 (74.32 Million). Also see total assets of BioArctic AB (publ) for a full breakdown of the balance sheet.
BioArctic AB (publ) Market Cap History: 2017 to 2026
BioArctic AB (publ)'s market capitalization history from 2017 to 2026. Data shows growth from $203.83 Million to $2.54 Billion (31.02% CAGR). Also see BIOA-B cash flow metrics for how efficiently the company converts equity into cash flow.
BioArctic AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioArctic AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BioArctic AB (publ) (BIOA-B) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.24x
BioArctic AB (publ)'s market cap is 1.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.43x
BioArctic AB (publ)'s market cap is 2.43 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $203.83 Million | $140.71 Million | $15.16 Million | 1.45x | 13.45x |
| 2018 | $642.85 Million | $713.97 Million | $381.60 Million | 0.90x | 1.68x |
| 2019 | $759.06 Million | $281.77 Million | $88.47 Million | 2.69x | 8.58x |
| 2020 | $763.06 Million | $62.35 Million | -$68.52 Million | 12.24x | N/A |
| 2021 | $953.42 Million | $23.15 Million | -$119.79 Million | 41.19x | N/A |
| 2022 | $2.18 Billion | $228.29 Million | -$11.18 Million | 9.53x | N/A |
| 2023 | $2.14 Billion | $616.00 Million | $229.25 Million | 3.48x | 9.34x |
| 2024 | $1.60 Billion | $257.35 Million | -$177.08 Million | 6.20x | N/A |
| 2025 | $2.49 Billion | $2.00 Billion | $1.02 Billion | 1.24x | 2.43x |
Competitor Companies of BIOA-B by Market Capitalization
Companies near BioArctic AB (publ) in the global market cap rankings as of September 16, 2026. Review BioArctic AB (publ) (BIOA-B) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BioArctic AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
BioArctic AB (publ) Historical Marketcap From 2017 to 2026
Between 2017 and today, BioArctic AB (publ)'s market cap moved from $203.83 Million to $ 2.54 Billion, with a yearly change of 31.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr2.54 Billion | +2.12% |
| 2025 | Skr2.49 Billion | +55.79% |
| 2024 | Skr1.60 Billion | -25.50% |
| 2023 | Skr2.14 Billion | -1.54% |
| 2022 | Skr2.18 Billion | +128.19% |
| 2021 | Skr953.42 Million | +24.95% |
| 2020 | Skr763.06 Million | +0.53% |
| 2019 | Skr759.06 Million | +18.08% |
| 2018 | Skr642.85 Million | +215.39% |
| 2017 | Skr203.83 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of BioArctic AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.54 Billion USD |
| MoneyControl | $2.54 Billion USD |
| MarketWatch | $2.54 Billion USD |
| marketcap.company | $2.54 Billion USD |
| Reuters | $2.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers L… Read more